CN113244237B - Application of BI8622 in the preparation of drugs for alleviating cisplatin-induced acute kidney injury - Google Patents
Application of BI8622 in the preparation of drugs for alleviating cisplatin-induced acute kidney injury Download PDFInfo
- Publication number
- CN113244237B CN113244237B CN202110691103.7A CN202110691103A CN113244237B CN 113244237 B CN113244237 B CN 113244237B CN 202110691103 A CN202110691103 A CN 202110691103A CN 113244237 B CN113244237 B CN 113244237B
- Authority
- CN
- China
- Prior art keywords
- cisplatin
- acute kidney
- induced
- kidney injury
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 60
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 60
- 201000011040 acute kidney failure Diseases 0.000 title claims abstract description 32
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims abstract description 31
- 208000033626 Renal failure acute Diseases 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title description 7
- 102100035886 Adenine DNA glycosylase Human genes 0.000 claims abstract description 14
- 101001000351 Homo sapiens Adenine DNA glycosylase Proteins 0.000 claims abstract description 14
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 claims abstract description 12
- 230000005778 DNA damage Effects 0.000 claims abstract description 9
- 231100000277 DNA damage Toxicity 0.000 claims abstract description 9
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 11
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 230000001154 acute effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
- 230000034512 ubiquitination Effects 0.000 description 8
- 238000010798 ubiquitination Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000004926 tubular epithelial cell Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102100034533 Histone H2AX Human genes 0.000 description 5
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 5
- 206010061481 Renal injury Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000010024 tubular injury Effects 0.000 description 5
- 208000037978 tubular injury Diseases 0.000 description 5
- 108010051335 Lipocalin-2 Proteins 0.000 description 4
- 102000013519 Lipocalin-2 Human genes 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 208000037806 kidney injury Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 3
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 3
- 229940105442 cisplatin injection Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000007694 nephrotoxicity Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008971 epithelial apoptosis Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- -1 small molecule compounds Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel application of BI8622, namely an application of BI8622 in preparation of a medicine for relieving acute kidney injury induced by cisplatin. The application finds that BI8622 can be an effective clinical medicine for preventing and treating AKI by inhibiting the activity of E3 ubiquitinase HUWE1 and up-regulating the protein level of MUTYH to improve DNA damage and further relieve cisplatin-related acute kidney damage.
Description
Technical Field
The invention relates to a novel medicinal application of BI8622, in particular to an application of BI8622 in preparing a medicament for relieving acute kidney injury caused by cisplatin serving as a chemotherapeutic medicament.
Background
In the 70 s of the 20 th century, cisplatin began to be widely used clinically for treating various malignant tumors, including bladder cancer, cervical cancer, head and neck malignant tumors, small cell or non-small cell lung pain and the like, and is one of the most effective and commonly used chemotherapeutic drugs for treating solid tumors. However, cisplatin can cause serious adverse reactions such as damage to normal tissues and organs while killing tumor cells, thereby greatly limiting the clinical application of cisplatin. The adverse reactions of cisplatin mainly include a series of systemic organ injury reactions such as nephrotoxicity. Of these, nephrotoxicity is most common, and after cisplatin treatment, renal dysfunction has occurred in approximately 1/3 patients leading to acute renal failure, and its dose-related nephrotoxicity has greatly limited cisplatin clinical use. The mechanism of normal cell damage caused by cisplatin has not been completely understood for a long time, and numerous studies have found that DNA damage, inflammatory mediators, necrosis, iron death, apoptosis, oxidative stress, autophagy, etc. may be the cause of normal tissue organ damage caused by cisplatin (Ozkok A, Edelstein CL. Pathophysiology of pain-induced access kit in J.BioMed research international 2014; 2014: 967826).
Although the platinum chemotherapeutic drugs have been gradually replaced by new chemotherapeutic drugs in recent years, the traditional platinum drugs and derivatives thereof are still widely applied to clinical antitumor chemotherapeutic drugs due to the effective effect of the platinum drugs and derivatives thereof in antitumor. However, the toxic and side effects of the kidney injury and the like caused by the platinum drugs greatly limit the clinical application of the drugs, and at present, an effective drug for treating the acute kidney injury induced by the cisplatin is still lacking clinically, so that the development of a new effective drug capable of improving the acute kidney injury caused by the cisplatin has important clinical significance.
HUWE1 inhibitor BI8622 is a class of small molecule compounds having the following structural formula:
BI8622 is obtained by screening of Stefanie Peter et al, can specifically inhibit ubiquitin ligase HUWE1 through ubiquitination modification function, and finds that the inhibitor has a certain inhibiting effect on tumorigenesis and development (Peter S, Bumultick J, Myant K, Jaenicke LA, Walz S, Muller J, et al. Tumor cell-specific inhibition of MYC functional using small molecule inhibitors of the HUWE1ubiquitin Ligase. EMBO Mol. Med. 2014; 6: 5. 1541.), CN111358793A discloses that HUWE1 inhibitor BI8622 can be used for inhibiting activation of the inflammasome, but no published literature exists yet that BI8622 can reduce acute kidney injury induced by cisplatin.
Disclosure of Invention
The application unexpectedly finds that the level of the MUTYH protein in the kidney tissue of the mouse with acute kidney injury induced by cisplatin is remarkably reduced, and the E3 ubiquitination ligase HUWE 1-mediated MUTYH ubiquitination degradation is probably a molecular mechanism, which suggests that the inhibition of HUWE1 function by using a related inhibitor may improve the DNA injury induced by cisplatin so as to improve the acute injury, and further the experiment verifies the speculation.
Specifically, the invention provides an application of a ubiquitin ligase HUWE1 protein inhibitor BI8622 in preparation of an acute kidney injury medicament, and the application of the inhibitor in preparation of a medicament for relieving cisplatin-induced acute kidney injury related symptoms solves the technical problem that no suitable medicament is available in the prior art for treating cisplatin-induced kidney structural and functional damage.
Specifically, the application proposes that BI8622 improves DNA damage by inhibiting the activity of E3 ubiquitinase HUWE1, up-regulating MUTYH protein levels, and thereby reduces cisplatin-related acute kidney injury.
The invention uses BI8622 on a mouse model and an in vitro cell model of acute kidney injury induced by cisplatin, and discusses the application of BI8622 as an inhibitor of ubiquitin-mediated enzyme HUWE1 in medicaments for relieving acute kidney injury related diseases induced by cisplatin. The results show that intervention treatment by using BI8622 on a cisplatin mouse model and in vitro cells can obviously improve the acute kidney injury kidney structure and function, DNA injury, renal tubular cell apoptosis and the like; our findings will most likely provide effective clinical drugs for the prevention and treatment of AKI.
Drawings
Fig. 1 shows that BI8622 significantly improved kidney injury and kidney function in cisplatin-induced acute kidney injury;
FIG. 2 shows that BI8622 down-regulates NGAL and KIM-l protein levels in renal tissue in a cisplatin-induced acute kidney injury model;
fig. 3 shows that BI8622 significantly improved cisplatin-induced DNA damage;
fig. 4 shows that BI8622 significantly inhibits MUTYH ubiquitination and up-regulates its protein levels;
fig. 5 shows that BI8622 significantly reduced cisplatin-induced tubular epithelial apoptosis in an in vitro tubular epithelial cell model.
Detailed Description
The present invention will be described in further detail with reference to specific examples, which will help understanding the present invention, but the scope of the present invention is not limited to the following examples.
The materials and methods used in the following examples are as follows:
materials and reagents:
BI8622 available from MCE, USA; NGAL, MUTYH antibody was purchased from Abcam; KIM-1, antibody, available from R & D Systems; clean caspase3, gamma H2AX, purchased from CST; beta-actin antibodies were all purchased from proteintech; fluorescent secondary antibodies were purchased from Invitrogen; apoptosis detection kits were purchased from B & D.
(II) cell culture and treatment:
mouse tubular epithelial cells (mPTCs) were cultured in DMEM/F12 medium containing 10% fetal bovine serum, 0.5% penicillin and streptomycin at 37 ℃ in 5% carbon dioxide and 95% air. To investigate the role of BI8622 in cisplatin-induced injury to tubular epithelial cells, mPTC was grown to 70% density and replaced with DMEM/F12 medium without fetal bovine serum, and BI8622 (dissolved in DMSO) was added for 1h or treated identically with DMSO. After the cells are incubated in an incubator for 24h, the cells are finally collected to carry out tests such as Western Blot detection, flow cytometry analysis of apoptosis and the like.
(III) cisplatin-induced acute renal injury mouse model and experimental grouping:
mice were randomized into four groups of 6 mice, each group consisting of a placebo group (vehicle), a BI8622 group, a cisplatin injection model group (cissplatin), and a cissplatin + BI8622 group (cissplatin + BI 8622). BI8622 was dissolved in PEG300+ TWEEN80+ DMSO and administered by intraperitoneal injection at a dose of 5 mg/kg. Mice in the control group or BI 8622-treated group were given either vehicle or BI8622, respectively, by intraperitoneal injection once a day starting 12h before cisplatin injection. Cisplatin model mice were injected with 20mg/kg of cisplatin at a time intraperitoneally, and mice were sacrificed and harvested 72h after cisplatin injection. Mice in the control group received the same dose of saline injection. After 72 hours, all groups of mice were euthanized and kidney and blood samples were collected. All animal experiments followed the Chinese regulations for the management and use of experimental animals.
(IV) renal function detection:
blood serum components are collected after a mouse blood specimen is centrifuged, and serum creatinine and serum urea nitrogen indexes are detected on a full-automatic biochemical instrument of children hospital in Nanjing.
(V) renal tubular injury score:
the degree of tubular injury was observed in the pathological staining of PAS in the kidney and evaluated according to a semi-quantitative injury score with 0 score for normal tubular tissue, 1 score for 30% of tubular injury, 2 scores for 30% -60% of tubular injury and 3 scores for greater than 60%.
(VI) histological and immunofluorescence staining:
kidney tissues are fixed by paraformaldehyde, wrapped by paraffin, and subjected to histology and immunofluorescence staining after being sliced.
Primary antibody concentrations of γ H2AX, etc. were all 1:100, fluorescent secondary antibody concentrations were 1:400, DAPI staining was performed as indicated.
(seventh) western immunoblotting:
the kidney tissue extracts proteins and operates according to literature procedures. Results of Western immunoblotting (Western blot) were subjected to grayscale analysis using ImageJ software.
(eight) flow cytometric detection of apoptosis:
culturing mouse renal tubular epithelial cells, pretreating with BI8622 for 1h, adding cisplatin for 24h, analyzing apoptosis level of the cells by a flow cytometer, and repeating cell experiments for three times and counting.
(nine) statistical analysis:
data are represented using the mean SD. Multiple comparisons were performed using one-way analysis of variance (ANOVA) and two data comparisons were performed using T-test. P <0.05 is statistically significant.
Example 2BI8622 improves kidney injury and kidney function in a cisplatin-induced acute kidney injury model.
In order to evaluate and detect the effect of BI8622 in protection of cisplatin-induced acute kidney injury, related biochemical indexes of kidney in mouse serum are detected, after 72 hours of intraperitoneal cisplatin modeling, indexes of serum muscle and urea nitrogen are obviously increased, and pathological injury manifestations of kidney such as renal tubular dilatation necrosis are also serious, while after BI8622 treatment, corresponding kidney injury and kidney function indexes are obviously reduced (fig. 1A, 1B and 1C). In addition, the renal tubular injury score also suggests that trehalose treatment may ameliorate cisplatin-induced pathological renal injury. Thus, BI8622 may not only improve kidney function, but also reduce pathological damage to the kidney. These results indicate that BI8622 can protect cisplatin-induced acute kidney injury and has no significant toxic side effects by itself.
To further demonstrate the role of BI8622 in protecting cisplatin-induced acute kidney injury, we examined specific biomarkers, NGAL and KIM-1, early in acute kidney injury. As shown in fig. 2, the western blot detection results show that KIM-1 and NGAL are highly expressed in the kidney of cisplatin-induced acute kidney injury mice, and the expression level thereof is significantly reduced after BI8622 treatment, which indicates that BI8622 can improve cisplatin-induced acute kidney injury.
Example 3 in the cisplatin-induced acute kidney injury model, BI8622 significantly improved cisplatin-induced DNA damage.
The main principle that cisplatin acts on cells is that cisplatin enters cell nucleus and is combined with DNA to form a DNA-platinum complex, so that DNA damage is caused, therefore, the DNA damage level in mouse kidney tissues after BI8622 treatment is further detected, comet-event electrophoresis can detect the DNA breakage level, and the result shows that BI8622 remarkably improves cisplatin-induced DNA double strand breakage (fig. 3A); further, γ H2AX protein levels could indicate DNA fragmentation, and γ H2AX immunofluorescent staining showed that cisplatin-induced upregulation of γ H2AX levels was significantly down-regulated following BI8622 treatment (fig. 3B). The above results suggest that BI8622 can significantly improve cisplatin-induced DNA damage.
Example 4 BI8622 inhibits cisplatin-induced ubiquitination of the MUTYH protein and up-regulates its protein levels in a cisplatin-induced acute kidney injury model.
We further explored the possible mechanism of action of BI8622, which could act as an inhibitor of E3 ubiquitin ligase HUWE1 by regulating ubiquitination of substrate proteins. One of the substrate proteins of HUWE1, MUTYH, is a glycosylase which is widely expressed in mammalian cells and participates in the repair of base mismatch excision, and plays an important role in the repair of DNA oxidative damage. Our experimental results show that treatment with BI8622 can significantly down-regulate cisplatin-induced levels of MUTYH ubiquitination (fig. 4A); thereby significantly improving cisplatin-induced down-regulation of MUTYH protein levels (figure 4B).
Example 5 in an in vitro cisplatin model of tubular epithelial cells, BI8622 treatment improved cisplatin-induced apoptosis.
Further, using tubular epithelial cells cultured in vitro, pre-treating for 1h with BI8622(1 μ M), then adding 5g/ml cisplatin to continue treating for 24h, collecting cells and detecting the apoptosis level by a flow cytometer, and the result shows that BI8622 can significantly improve cisplatin-induced apoptosis (fig. 5A); further, western blot results showed that apoptosis-related protein clear caspase3 was significantly down-regulated after BI8622 treatment, while cisplatin-induced down-regulation of MUTYH protein levels was significantly improved (fig. 5B).
In conclusion, the invention provides an application of HUWE1 ubiquitinase inhibitor BI8622 in preparation of a medicine for relieving cisplatin-induced acute kidney injury related symptoms, the medicine is administered by intraperitoneal injection, the mouse dose is 5mg/kg, and the MUTYH protein level is up-regulated by inhibiting MUTYH ubiquitination degradation, so that DNA injury is improved, and acute kidney injury is improved.
Claims (2)
- Use of BI8622 in the manufacture of a medicament for the reduction of cisplatin-induced acute kidney injury.
- 2. The use of claim 1, wherein BI8622 ameliorates DNA damage by inhibiting the activity of E3 ubiquitinase HUWE1, up-regulating MUTYH protein levels, thereby reducing cisplatin-related acute kidney injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110691103.7A CN113244237B (en) | 2021-06-22 | 2021-06-22 | Application of BI8622 in the preparation of drugs for alleviating cisplatin-induced acute kidney injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110691103.7A CN113244237B (en) | 2021-06-22 | 2021-06-22 | Application of BI8622 in the preparation of drugs for alleviating cisplatin-induced acute kidney injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113244237A CN113244237A (en) | 2021-08-13 |
| CN113244237B true CN113244237B (en) | 2022-03-04 |
Family
ID=77189091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110691103.7A Active CN113244237B (en) | 2021-06-22 | 2021-06-22 | Application of BI8622 in the preparation of drugs for alleviating cisplatin-induced acute kidney injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113244237B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111358793B (en) * | 2020-03-13 | 2021-08-10 | 中国科学院昆明动物研究所 | Novel application of HUWE1 inhibitor BI8622 |
-
2021
- 2021-06-22 CN CN202110691103.7A patent/CN113244237B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113244237A (en) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111358789B (en) | Application of NSC228155 in preparation of medicine for preventing and treating chronic renal fibrosis | |
| Li et al. | Gefitinib inhibits bleomycin‐induced pulmonary fibrosis via alleviating the oxidative damage in mice | |
| CN111358790B (en) | Use of NSC228155 in the preparation of medicines for preventing and treating acute kidney injury | |
| Zhang et al. | Effects of tristetraprolin on doxorubicin (adriamycin)-induced experimental kidney injury through inhibiting IL-13/STAT6 signal pathway | |
| CN110200972A (en) | Purposes of the KD025 in the drug that preparation prevents and treats chronic kidney fibrosis | |
| CN108434139B (en) | Application of hypoxia-inducible factor prolyl hydroxylase activity inhibitor in preparation of medicine for preventing and treating acute kidney injury | |
| Huang et al. | 3-Hydroxybutyrate ameliorates sepsis-associated acute lung injury by promoting autophagy through the activation of GPR109α in macrophages | |
| Jiao et al. | Amygdalin epimers exert discrepant anti-pulmonary fibrosis activity via inhibiting TGF-β1/Smad2/3 pathway | |
| CN113244237B (en) | Application of BI8622 in the preparation of drugs for alleviating cisplatin-induced acute kidney injury | |
| CN114177179A (en) | Application of YM-155 in medicine for preventing and treating chronic kidney diseases | |
| Wang et al. | Olfactomedin-4 deletion exacerbates DSS-induced colitis through a matrix metalloproteinase-9-dependent mechanism | |
| Wen et al. | Insulin reverses impaired alveolar fluid clearance in ARDS by inhibiting LPS-induced autophagy and inflammatory | |
| CN113855684B (en) | Use of orisoxime in the preparation of a medicament for alleviating or improving cisplatin-induced acute kidney injury | |
| Huang et al. | Kaempferol suppresses inflammation in mice suffering from both hyperuricemia and gouty arthritis through inhibiting NLRP3 inflammasome and NF-κB pathway | |
| CN112791086A (en) | Use of C16 in the preparation of drugs for preventing and treating chronic renal interstitial fibrosis | |
| CN116115606A (en) | Application of Xanthoxol in preparing medicament for treating cisplatin-induced acute kidney injury | |
| CN113440596A (en) | Application of Epitalon in preparation of medicine for relieving acute kidney injury induced by cisplatin | |
| CN115813901B (en) | Application of 3-phenyl glutaric acid derivative small molecule in preparation of medicament for preventing and treating cisplatin-induced acute kidney injury | |
| CN114907287B (en) | A compound for treating kidney damage | |
| CN113244276B (en) | Use of Sang Huanghuo Phellinus linteus extract as novel coronavirus therapeutic drug or antiviral agent | |
| Ji et al. | Szechwan Lovage Rhizome Extract Improves Renal Function and Alleviates Inflammatory Responses in Pyelonephritis Rats Infected with Escherichia Coli via IL-6/STAT3 Axis | |
| Chen et al. | Ursolic acid inhibits NLRP3 inflammasome activation and alleviates vascular smooth muscle injury in Kawasaki disease. | |
| CN117771259A (en) | Application of tiliroside in preparation of medicine for relieving acute kidney injury | |
| CN119097713A (en) | Application of BCAT1 inhibitor in preparation of medicines for treating fibrosis diseases | |
| CN117379441A (en) | Application of Cinobufostalin in the preparation of drugs for the treatment of pulmonary fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |